Abstract
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA), mainly affecting the kidney. The disease is characterized by microangiopathic hemolytic anemia, thrombocy-topenia, and acute kidney injury. It is one of the most common causes of acute kidney injury in children. Under this umbrella, there are several different disorders: Shiga toxin-associated HUS, Streptococcus pneumoniae-associated HUS, and HUS associated with complement dys-regulation. Several drugs and conditions may also cause HUS. There are many different classi-fication systems, which have been developed during the history of the disease. In recent years, clinical and experimental studies have revealed abnormalities in different pathways beyond complement system. Besides, therapeutic options that are based on the pathophysiology have been available for HUS patients.
| Original language | English |
|---|---|
| Pages (from-to) | 415-422 |
| Number of pages | 8 |
| Journal | Turkish Archives of Pediatrics |
| Volume | 56 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sept 2021 |
Keywords
- Complement system
- Eculizumab
- Hemolytic uremic syndrome
Fingerprint
Dive into the research topics of 'Hemolytic uremic syndrome in children'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver